Highlights

  • The 10-Q states that going concern doubt exists for 12 months from the date the financial statements were issued.
  • Cash, cash equivalents and investments were $95.1 million at June 30, 2026, and the accumulated deficit was $979.6 million.
  • Net loss for the quarter ended June 30, 2026 was $42,109 thousand, or $0.24 per share, compared with $0.41.
  • The FDA cleared the PM577a IND application in July 2026, and a July 6 final arbitration award went to the company.

Prime Medicine, Inc. (NASDAQ: PRME) shares were trading at USD 4.08 on October 27, 2026, up 13.02%, with a relative volume at time of 2.09. The biotechnology company received clearance of the CTA for PM577a in New Zealand in June 2026, received a final arbitration award on July 6, and filed its Form 10-Q for the quarter ended June 30, 2026 on August 6.

Prime Medicine is a Delaware corporation with principal executive offices at 60 First Street in Cambridge, Massachusetts. It is a biotechnology company developing genetic medicines based on Prime Editing, designed to treat diseases associated with defined genetic alterations, acquired cellular dysfunction or dysregulated gene expression. Its in vivo programs target Wilson disease and alpha-1 antitrypsin deficiency (AATD), and it also advances an in vivo Cystic Fibrosis program and Prime Edited CAR-T products in partnership with BMS. It has not generated revenue from product sales. Its fiscal year ends December 31.

Second Quarter 2026 Results

The figures below are unaudited and cover the three months ended June 30, 2026. Collaboration revenue from a related party was $1,154 thousand, compared with $1,115 thousand. Research and development expenses were $33,397 thousand, compared with $41,375 thousand, and general and administrative expenses were $11,042 thousand, compared with $13,117 thousand.

Loss from operations was $43,285 thousand, compared with $53,377 thousand. Net loss attributable to common stockholders was $42,109 thousand, or $0.24 per share, compared with $52,591 thousand, or $0.41 per share. For the six months, net loss was $91,231 thousand, or $0.51 per share, and net cash used in operating activities was $83,756 thousand.

Going Concern, Cash and Financing

As of June 30, 2026, Prime Medicine had cash, cash equivalents and investments of $95.1 million, excluding restricted cash, or $108.8 million including restricted cash. The accumulated deficit was $979.6 million, and the company expects operating losses and negative operating cash flows for the foreseeable future.

The company evaluated its ability to continue as a going concern and concluded, under ASC 205-40, that doubt exists for 12 months from the date the financial statements were issued. It said its ability to continue depends on obtaining financing, that management plans to use financing or other transactions and its at-the-market program, and that there is no assurance it can raise additional capital on acceptable terms or at all. It also said it believes existing cash, cash equivalents and investments will fund operations into 2027.

The company has a registration statement for the issuance of up to $500.0 million of securities and a Sales Agreement with Jefferies for at-the-market sales of common stock with aggregate sales proceeds of up to $300.0 million. It said additional equity financing may dilute ownership interests and that it may need to delay, reduce or eliminate development efforts if it cannot raise funds.

Pipeline and Legal Developments

In June 2026, the company received CTA clearance for PM577a, an investigational Prime Editor for Wilson disease, in New Zealand, enabling a global Phase 1/2 clinical trial. In July 2026, the FDA cleared the IND application for PM577a. The company said it is on track for an IND application submission and/or CTA filing in the third quarter of 2026 for PM647 in AATD.

In June 2026, the FDA granted RMAT designation for PM359 in chronic granulomatous disease. The company said it is in regulatory dialogue with the FDA toward a Biologics License Application submission for PM359, planned for the first half of 2027.

On July 6, 2026, an arbitration tribunal issued a final award declaring that PM647 is within the company's Field under the Beam Collaboration Agreement and that the company did not breach it. The tribunal denied Beam's requests for damages and injunctive relief and denied the remaining claims brought by both parties.